PLX Protalix BioTherapeutics, Inc.
P/E
11.173913
Forward P/E
4.145161
Price/Sales
2.56849
Beta
-0.088
Div Yield
0.0%
Market Cap
--
Company Analysis
Latest News
Protalix BioTherapeutics beats third quarter 2026 estimates with $21.9M revenue and reaffirms annual guidance
Protalix BioTherapeutics reported third quarter 2026 results that significantly outperformed analyst expectations, driven by higher goods sales to commercial...
Protalix BioTherapeutics, Inc. Q3 2026 Earnings Preview: What Analysts Expect on November 10, 2026
Protalix BioTherapeutics is projected to report Q3 2026 revenue of $12.4 million and an EPS loss of $0.02, with its current $2.54 share price sitting...